Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue #1277, Wuhan, 430022, China.
Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China.
BMC Cancer. 2024 Nov 18;24(1):1422. doi: 10.1186/s12885-024-13179-5.
The aim of this study was to investigate the efficacy and safety of the combined treatment regimen of D-TACE, HAIC, and Lenvatinib in patients with massive hepatocellular carcinoma, with the goal of providing a safer and more effective therapeutic strategy for individuals suffering from massive hepatocellular carcinoma.
A retrospective analysis was conducted using clinical data from 118 patients with unresectable massive hepatocellular carcinoma who underwent treatment at the Interventional Department of Wuhan Union Hospital between June 2018 and December 2021. Based on the treatment approach, the patients were divided into two groups: the D-TACE + HAIC + Lenvatinib group (N = 54) and the D-TACE + Lenvatinib group (N = 64). The primary study endpoints included the objective response rate (ORR), disease control rate (DCR), overall survival (OS), and progression-free survival (PFS) of the two groups. Additionally, the occurrence of treatment-related adverse events in both groups was considered as a secondary study endpoint.
Following the treatment, the D-TACE + HAIC + Lenvatinib group exhibited significantly higher ORR and DCR compared to the D-TACE + Lenvatinib group (68.5% vs. 43.8%, 90.7% vs. 73.4%, P < 0.05). Moreover, the D-TACE + HAIC + Lenvatinib group demonstrated longer mPFS and mOS in comparison to the D-TACE + Lenvatinib group (8.6 months vs. 6.6 months, P = 0.005; 19.5 months vs. 14.1 months, P < 0.001). There was no statistically significant difference in the occurrence rate of common treatment-related adverse events between the TACE + HAIC + Lenvatinib group and the D-TACE + Lenvatinib group (P > 0.05).
The combined treatment regimen of D-TACE, HAIC, and Lenvatinib demonstrated superior therapeutic efficacy and safety in managing unresectable massive hepatocellular carcinoma. This combination therapy may serve as a viable option for improving the prognosis of patients with unresectable massive hepatocellular carcinoma.
本研究旨在探讨 D-TACE、HAIC 和乐伐替尼联合治疗不可切除的大肝癌患者的疗效和安全性，为大肝癌患者提供更安全、更有效的治疗策略。
回顾性分析 2018 年 6 月至 2021 年 12 月在武汉协和医院介入科治疗的 118 例不可切除的大肝癌患者的临床资料。根据治疗方法将患者分为 D-TACE+HAIC+乐伐替尼组（n=54）和 D-TACE+乐伐替尼组（n=64）。主要研究终点为两组的客观缓解率（ORR）、疾病控制率（DCR）、总生存期（OS）和无进展生存期（PFS）。同时，观察两组患者的治疗相关不良反应发生情况作为次要研究终点。
治疗后，D-TACE+HAIC+乐伐替尼组的 ORR 和 DCR 明显高于 D-TACE+乐伐替尼组（68.5% vs. 43.8%，90.7% vs. 73.4%，P<0.05）。D-TACE+HAIC+乐伐替尼组 mPFS 和 mOS 明显长于 D-TACE+乐伐替尼组（8.6 个月 vs. 6.6 个月，P=0.005；19.5 个月 vs. 14.1 个月，P<0.001）。两组常见治疗相关不良反应发生率差异无统计学意义（P>0.05）。
D-TACE、HAIC 和乐伐替尼联合治疗不可切除的大肝癌具有较好的疗效和安全性，为提高不可切除的大肝癌患者的预后提供了一种新的选择。
